Last Updated: 10 Nov 2024
Executive Summary
Evoke Pharma Inc. (EVOK) is a specialty pharmaceutical company focused on developing and commercializing drugs for gastroenterological diseases. The company's latest stock price is $5.65, and its market capitalization is $4.6 million. EVOK has a strong pipeline of drugs in development, including its lead product, Gimoti, which is approved for the treatment of opioid-induced constipation. The company also has a number of other drugs in development for the treatment of gastrointestinal disorders, including irritable bowel syndrome and Crohn's disease.
Company Overview
Evoke Pharma was founded in 2013 and is headquartered in Solana Beach, California. The company's mission is to develop and commercialize innovative therapies that improve the lives of patients with gastrointestinal disorders. EVOK has a team of experienced scientists and executives with a deep understanding of the gastrointestinal market.
Fundamental Analysis
EVOK's financial performance has been mixed in recent years. The company has reported losses in each of the past three years, and its revenue has been declining. However, the company's pipeline of drugs in development has the potential to drive future growth.
Revenue: EVOK's revenue declined by 1.25% in the most recent quarter, to $7.5 million. This decline was due to a decrease in sales of the company's lead product, Gimoti.
Gross profit: EVOK's gross profit margin was 28.4% in the most recent quarter, up from 27.1% in the same quarter last year. This improvement was due to a decrease in the cost of goods sold.
Net income: EVOK reported a net loss of $16 million in the most recent quarter, compared to a net loss of $15.1 million in the same quarter last year. This increase in the net loss was due to an increase in operating expenses.
EPS: EVOK's EPS was -$0.20 in the most recent quarter, compared to -$0.19 in the same quarter last year.
Technical Analysis
EVOK's stock price has been in a downtrend since early 2022. The stock has been trading below its 50-day and 200-day moving averages, and it has recently broken below a key support level at $6.00. The stock's technical indicators are also bearish, with the RSI and MACD both below 50.
Short Term Outlook
The short-term outlook for EVOK is bearish. The stock is in a downtrend, and it has recently broken below a key support level. The stock's technical indicators are also bearish. Investors should expect the stock to continue to decline in the short term.
Long Term Outlook
The long-term outlook for EVOK is more positive. The company has a strong pipeline of drugs in development, and it has a team of experienced scientists and executives with a deep understanding of the gastrointestinal market. If EVOK can successfully develop and commercialize its drugs, it has the potential to be a successful company.
Analyst Recommendations
Analysts are mixed on EVOK. One analyst has a buy rating on the stock, while another has a hold rating. The average analyst price target is $18.00.
